Mr. COVID & MIS-C: One Toxic Relationship

<p>Natalie A. Haddad, PharmD (<a href='https://twitter.com/NatalieHaddadRx'>@NatalieHaddadRx</a>) describes the epidemiology of multisystem inflammatory syndrome in children (MIS-C), outlines key similarities and differences between MIS-C and other comparable pediatric conditions and discusses current potential therapeutic options for the treatment of MIS-C.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>